aTYR PHARMA Executive Compensation (FY25)
ATYR · Executive and director compensation, fiscal 2024 to 2025
The aTYR PHARMA brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 19, 2026Latest filing (DEF 14A): March 26, 2026
7 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
110 figures on this page: 105 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Sanjay Shukla: $1,480,522 → $3,456,253 (133.4% higher)
Say-on-pay support: 99.1% → 97.6% (1.5 points lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is aTYR PHARMA's chief executive and what were they paid?
Sanjay Shukla was paid $3,456,253 in total compensation as President and Chief Executive Officer for fiscal 2025. Compared with the $1,480,522 reported for fiscal 2024, Shukla's total was 133.4% higher.
What was aTYR PHARMA's say-on-pay result?
The say-on-pay proposal drew 97.6% of votes cast for or against in favor at the meeting held May 1, 2025 for fiscal 2024.
Which companies are in aTYR PHARMA's peer group?
The disclosed peer group includes Acelyrin, Inc., Alector, Inc., Allakos Inc., Altimmune, Inc. and Fortress Biotech, Inc., among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Sanjay Shukla President and Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Jill Broadfoot Chief Financial Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Nancy Denyes General Counsel and Corporate Secretary | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Sanjay Shukla President and Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Jill Broadfoot Chief Financial Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Nancy Denyes General Counsel and Corporate Secretary | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Jill Broadfoot | Option | — | — | — | — | — | — | ◇ |
| Nancy Denyes | Option | — | — | — | — | — | — | ◇ |
| Sanjay Shukla | Option | — | — | — | — | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Jill Broadfoot | Option | ◇ | — | ◇ | 1/5/2034 |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/8/2035 | |
| Option | ◇ | — | ◇ | 2/16/2033 | |
| Option | ◇ | — | ◇ | 2/3/2032 | |
| Option | ◇ | — | ◇ | 5/24/2032 | |
| Sanjay Shukla | Option | ◇ | — | ◇ | 2/16/2033 |
| Option | ◇ | — | ◇ | 5/24/2032 | |
| Option | ◇ | — | ◇ | 2/3/2032 | |
| Option | ◇ | — | ◇ | 1/5/2034 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/8/2035 | |
| Nancy Denyes | Option | ◇ | — | ◇ | 2/16/2033 |
| Option | ◇ | — | ◇ | 1/5/2034 | |
| Option | ◇ | — | ◇ | 1/8/2035 | |
| Option | ◇ | — | ◇ | 5/24/2032 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/3/2032 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Svetlana Lucas, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Jane A. Gross, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Sara L. Zaknoen, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Eric Benevich | ◇ | — | ◇ | — | — | — | ◇ |
Paul Schimmel, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
John K. Clarke | ◇ | — | — | — | — | — | ◇ |
Timothy P. Coughlin and Sanjay S. Shukla, M.D., M.S served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Compensation committee chair | ◇ |
| Nominating and governance chair | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Acelyrin, Inc. symbol not shown
- Alector, Inc. ALEC
- Allakos Inc. ALLK
- Altimmune, Inc. ALT
- Fortress Biotech, Inc. symbol not shown
- Gossamer Bio, Inc. GOSS
- Immunic, Inc. symbol not shown
- Jasper Therapeutics, Inc. JSPR
- KalVista Pharmaceuticals, Inc. KALV
- Kezar Life Sciences, Inc. KZR
- Longboard Pharmaceuticals, Inc. LBPH
- Pliant Therapeutics, Inc. PLRX
- Savara Inc. SVRA
- Scholar Rock Holding Corporation SRRK
- Trevi Therapeutics, Inc. TRVI
- X4 Pharmaceuticals, Inc. XFOR
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2024 | May 1, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | May 22, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | May 17, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | April 26, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | April 28, 2021 | = | ◇ | ◇ | ◇ |
What this page does not include
Everything above is a fact aTYR PHARMA disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where aTYR PHARMA sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
110 figures on this page: 105 cited to the filing that reported them, 5 calculated from figures it prints.
105 cited to the filing
5 calculated from the filing
Documents cited
- 0001339970-26-000021DIRECTOR COMPENSATION · Director Compensation Table—2025 · Outstanding Equity Awards at Fiscal Year-End · SUMMARY COMPENSATION TABLE
- 0000950170-25-064413Proposal 3 – Approval, on an advisory basis, of the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.
- 0000950170-25-041992Summary Compensation Table
- 0000950170-24-065899Proposal 3 – Approval, on an advisory basis, of the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.
- 0000950170-23-023257Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001564590-22-016548Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001564590-21-023319Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “aTYR PHARMA executive compensation, FY2024–FY2025.” https://intel.velarion.ai/comp/ATYR (accessed 2026).
Short form: data: Velarion
The aTYR PHARMA brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
7 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about aTYR PHARMA and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers aTYR PHARMA discloses
The companies named in ATYR's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}